Stockscreener 앱 받기
1.74
4.19%
0.07
시간 외 거래:
1.73
-0.01
-0.57%
Longeveron Inc 주식(LGVN)의 최신 뉴스
Longeveron Inc. Stock Analysis and ForecastFree Wealth Management Insights - Autocar Professional
Is Longeveron Inc. a good long term investmentExplosive earnings growth - jammulinksnews.com
How Longeveron Inc. stock performs during market volatilityIntraday Trade Ideas - Newser
What drives Longeveron Inc. stock priceHigh-impact investment strategies - jammulinksnews.com
What analysts say about Longeveron Inc. stockExceptional profit margins - jammulinksnews.com
Published on: 2025-07-22 07:30:15 - Autocar Professional
Longeveron licenses stem cell patent for heart disease treatment - Investing.com
Longeveron licenses stem cell patent for heart disease treatment By Investing.com - Investing.com Nigeria
Longeveron Licenses US Patent for Advanced Cardiomyogenic Cell Technology from University of Miami - Nasdaq
Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease - The Manila Times
Revolutionary Heart Disease Breakthrough: Longeveron Licenses Safer Cardiac Stem Cell Technology - Stock Titan
What makes Longeveron Inc. stock price move sharplyFree Exclusive Stock Market Insights - Newser
Why Longeveron Inc. stock attracts strong analyst attentionLong Term Safe Yield Focus - Newser
Longeveron (LGVN) gets FDA nod to start Phase 2 laromestrocel trial | PLUG SEC FilingForm 424B7 - Stock Titan
Longeveron receives FDA approval for pediatric heart therapy IND By Investing.com - Investing.com South Africa
Longeveron®? Announces U.S. FDA Approval of IND Application for A Phase 2 Pivotal Registration Study Evaluating Laromestrocel as A Treatment of Pediatric Dilated Cardiomyopathy - MarketScreener
Longeveron® announces U.S. FDA approval of IND application - MarketScreener
Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM) - The Manila Times
Longeveron stock soars after FDA approves IND for heart failure treatment - Investing.com Nigeria
Longeveron stock soars after FDA approves IND for heart failure treatment By Investing.com - Investing.com South Africa
Longeveron Inc. Receives FDA Approval for IND Application to Advance Clinical Trial of Stem Cell Therapy for Pediatric Dilated Cardiomyopathy - Nasdaq
Breakthrough: FDA Fast-Tracks New Stem Cell Therapy for Fatal Children's Heart Condition - Stock Titan
Longeveron (NASDAQ:LGVN) Shares Down 1.5% – What’s Next? - Defense World
Longeveron appoints Than Powell as chief business officer - Investing.com
Longeveron (LGVN) Appoints New Chief Business Officer to Lead Strategic Initiatives | LGVN Stock News - GuruFocus
Longeveron® Appoints Than Powell as Chief Business Officer - GlobeNewswire
Longeveron Appoints Than Powell as Chief Business Officer, Effective July 7, 2025 - MarketScreener
Longeveron completes enrollment in HLHS pediatric heart trial - Investing.com India
Longeveron completes enrollment in HLHS pediatric heart trial By Investing.com - Investing.com Nigeria
Alzheimer's & Brain Awareness Month 2025: Looking Back at Recent Progress in Cell and Gene Therapy - CGTLive®
Transcript : Longeveron Inc.Shareholder/Analyst Call - MarketScreener
4.91%
0.25%
자본화:
|
볼륨(24시간):